Welcome to our dedicated page for Eli Lilly and news (Ticker: LLY), a resource for investors and traders seeking the latest updates and insights on Eli Lilly and stock.
Eli Lilly & Co. develops and commercializes medicines across cardiometabolic disease, oncology, immunology, neuroscience and genetic medicine. Company news commonly covers product and pipeline developments for medicines such as Mounjaro, Zepbound, Foundayo, Omvoh, Verzenio, Jaypirca and Taltz, including clinical data, regulatory approvals and treatment-indication updates.
Lilly updates also include operating results, financial guidance, dividends, business development agreements and manufacturing expansion. Recent company communications highlight investment in active pharmaceutical ingredient capacity and genetic medicine production, alongside recurring disclosures about demand for diabetes, obesity, immune-disease and cancer therapies.
Eli Lilly and Company (NYSE: LLY) will participate in the 2021 Cantor Virtual Global Healthcare Conference on September 28, 2021. Patrik Jonsson, senior vice president and president of Lilly Immunology, will engage in a virtual fireside chat at 1:20 p.m. ET. Interested parties can access a live audio webcast on Lilly's Investor website, with a replay available for 90 days.
Lilly is dedicated to advancing healthcare through innovative medicines and remains committed to its founding mission of improving lives globally.
New research from Eli Lilly Company (NYSE: LLY) will be showcased at the ESMO Congress 2021 (September 16-21). Key findings include:
- Verzenio: Studies on high-risk early breast cancer and advanced breast cancer.
- Retevmo: Real-world data on medullary thyroid cancer and RET testing patterns in Europe.
- CYRAMZA: Insights on metastatic NSCLC and the impact of TP53 status.
- Sintilimab: Phase III trial results for esophageal and gastric cancers.
Posters available starting September 16, with mini-oral presentations on September 17.
Summary not available.
The FDA has granted Breakthrough Therapy designation for Jardiance (empagliflozin) for treating adults with heart failure with preserved ejection fraction (HFpEF). This follows promising results from the EMPEROR-Preserved trial, showing a 21% relative risk reduction in cardiovascular death or hospitalization. Jardiance is already approved for heart failure with reduced ejection fraction. HFpEF affects around 3 million adults in the U.S., with no proven treatment options available until now.
Eli Lilly has pledged nearly $1 million over three years in collaboration with the Helmsley Charitable Trust to enhance access to resources for children with type 1 diabetes (T1D). This initiative aims to provide camperships for low-income youth, ensuring inclusivity in diabetes camps nationwide. The funding will also assist camps in adapting to COVID-19 requirements. Lilly's long-term commitment to diabetes care emphasizes equity and improved access for communities, reflecting its ongoing mission to better lives affected by diabetes.
Eli Lilly and Company (NYSE: LLY) has initiated a cash tender offer for up to $1.5 billion of its outstanding debt securities. The offer includes various notes with different due dates and interest rates, such as the 4.150% Notes due 2059 and 3.950% Notes due 2049, among others. The early tender deadline is set for September 20, 2021, with the final expiration on October 4, 2021. Holders must tender their notes to receive an early tender premium and are subject to certain limitations outlined in the Offer to Purchase.
Eli Lilly and Company (NYSE: LLY) will participate in the Morgan Stanley 19th Annual Global Healthcare Conference on September 14, 2021. Michael Mason, Lilly's Senior Vice President and President of Lilly Diabetes, will engage in a virtual fireside chat at 1:15 p.m. Eastern Time. A live audio webcast of the event can be accessed on Lilly's Investor website, with a replay available for approximately 90 days. Lilly, a global healthcare leader, is dedicated to developing life-changing medicines and enhancing disease management.
Eli Lilly and Company (NYSE: LLY) will participate in Citi's 16th Annual BioPharma Virtual Conference on September 8-9, 2021. Senior Vice President and CFO Anat Ashkenazi will speak at a virtual fireside chat on September 9 at 9:45 a.m. ET. A live audio webcast will be available on Lilly's Investor website, with a replay accessible for about 90 days. Founded over a century ago, Lilly is committed to creating high-quality medicines and improving disease management globally.
Eli Lilly and Company (NYSE: LLY) announced the resignation of Carolyn R. Bertozzi, Ph.D., from its board of directors effective August 25, 2021. Her departure is linked to Lilly's collaboration with Lycia Therapeutics, Inc., where she is an academic founder. Bertozzi has served on the board since 2017, contributing her scientific expertise to Lilly's innovative pipeline. The CEO expressed gratitude for her service, highlighting her influence on technical and ethical decisions.
Eli Lilly and Company (NYSE: LLY) has entered a strategic collaboration with Lycia Therapeutics to discover and develop targeted therapeutics using Lycia's LYTAC technology. The partnership will focus on up to five targets in key areas like immunology and pain, addressing unmet medical needs. Lycia will receive an upfront payment of $35 million and may earn over $1.6 billion in milestone payments and royalties. Lilly is responsible for the development and commercialization of potential therapies, with no immediate impact on its 2021 earnings guidance.